Teniposide (VM-26) and continuous infusion cytosine at failure in childhood acute lymphoblastic leukemia. A pe

Cancer

66, 1671-1677

DOI: 10.1002/1097-0142(19901015)66:8<1671::aid-cncr2820660803>3.0.co;2-e

Citation Report

4

#	Article	IF	CITATIONS
1	Treatment of primary refractory or relapsed acute lymphoblastic leukemia (ALL) in children. Annals of Oncology, 1992, 3, 765-767.	0.6	8
2	Epipodophyllotoxins in the treatment of childhood cancer. Cancer Chemotherapy and Pharmacology, 1994, 34, S89-S95.	1.1	28
3	Induction failure in acute lymphoblastic leukemia of childhood. , 1999, 85, 1395-1404.		57
4	Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects. Leukemia, 2000, 14, 1736-1742.	3.3	35
5	Intermediate-Dose Methotrexate and Intravenous 6-Mercaptopurine Chemotherapy for Children With Acute Lymphoblastic Leukemia Who Did Not Respond to Initial Induction Therapy. Journal of Pediatric Hematology/Oncology, 2002, 24, 182-187.	0.3	5
6	Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. Journal of Clinical Oncology, 2008, 26, 1496-1503.	0.8	93
7	Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL Fâ€protocol. Pediatric Blood and Cancer, 2010, 54, 71-78.	0.8	34
8	Chemotherapy for Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2013, 35, 32-35.	0.3	2

9 Acute Lymphoblastic Leukemia. , 2009, , 295-330.